Trevi Therapeutics, Inc.

NasdaqGM:TRVI Stock Report

Market Cap: US$311.3m

Trevi Therapeutics Past Earnings Performance

Past criteria checks 0/6

Trevi Therapeutics's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.

Key information

-3.6%

Earnings growth rate

42.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equity-75.2%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Trevi adds 19% on full data set from mid-stage cough study

Sep 19

Trevi Therapeutics: Moving Forward

Sep 11

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Trevi has a new development chief

Feb 01

Revenue & Expenses Breakdown

How Trevi Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:TRVI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-441237
30 Jun 240-391232
31 Mar 240-341127
31 Dec 230-291024
30 Sep 230-271021
30 Jun 230-271021
31 Mar 230-281020
31 Dec 220-291020
30 Sep 220-321022
30 Jun 220-31921
31 Mar 220-33922
31 Dec 210-34923
30 Sep 210-351023
30 Jun 210-351023
31 Mar 210-331022
31 Dec 200-331022
30 Sep 200-30921
30 Jun 200-30921
31 Mar 200-29822
31 Dec 190-27719
30 Sep 190-28719
30 Jun 190-27617
31 Mar 190-27515
31 Dec 180-26414
30 Sep 180-22411
31 Dec 170-1326

Quality Earnings: TRVI is currently unprofitable.

Growing Profit Margin: TRVI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TRVI is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare TRVI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRVI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: TRVI has a negative Return on Equity (-75.15%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:56
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trevi Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.